A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer
Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2013.05.005
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2013
Authors
Publisher
Elsevier BV